A Patient-Centered Guide from Axios Health and Wellness
At Axios Health and Wellness, we believe men deserve clear, evidence-based answers—especially when it comes to testosterone replacement therapy (TRT) and prostate health. Few topics in men’s medicine have created more confusion than the relationship between testosterone, PSA (prostate-specific antigen), and prostate cancer.
For decades, men were told that testosterone “fuels” prostate cancer. That belief traces back to research in the 1940s by Charles Huggins and Clarence Hodges, who demonstrated that lowering testosterone caused regression of metastatic prostate cancer. Their work was groundbreaking and lifesaving for men with advanced disease. However, it involved men who already had metastatic cancer—not healthy men with low testosterone seeking hormone optimization.
Over time, this finding was generalized far beyond its original context, leading to widespread fear that restoring testosterone to normal levels would cause prostate cancer. Modern research tells a far more nuanced story.
Over the last three decades, high-quality clinical trials, large observational studies, and multiple meta-analyses have consistently shown that testosterone therapy—when prescribed appropriately and monitored carefully—does notincrease the risk of developing prostate cancer.
Recent large randomized trials involving thousands of hypogonadal men treated to physiologic testosterone levels found no higher incidence of prostate cancer compared with placebo groups. PSA levels may rise slightly during the first year of treatment, but they typically stabilize rather than continue rising. Large population studies involving more than 100,000 men similarly show no association between TRT and aggressive prostate cancer.
While ongoing long-term data continues to accumulate, the weight of current peer-reviewed evidence does not support the claim that TRT initiates prostate cancer.
PSA is a protein produced by prostate cells, and it is influenced by testosterone levels. This is where much of the misunderstanding begins.
When a man with low testosterone starts TRT, it is common to see a modest PSA increase—often around 0.3 to 0.5 ng/mL during the first year. This rise does not automatically mean cancer. In many cases, it reflects normalization of prostate activity as testosterone returns to a healthy physiologic range.
Only a small percentage of men experience PSA increases large enough to require further evaluation, and even then, most do not have prostate cancer. Monitoring PSA is important—but panic is not.
Modern research also supports the “androgen saturation model,” which proposes that prostate tissue is sensitive to testosterone only at very low levels. Once androgen receptors are saturated—typically within the low-normal range—additional testosterone does not significantly stimulate further prostate growth. This model helps explain why restoring testosterone to normal levels does not appear to drive cancer development.
What consistently stands out in the literature is that aging—not testosterone—is the dominant risk factor for prostate cancer.
Autopsy studies have demonstrated that:
Approximately 30% of men in their 50s have microscopic, undiagnosed prostate cancer.
By age 70, that number rises to 40–50%.
Many of these men had low testosterone levels for years. If testosterone were the primary driver of prostate cancer, we would expect younger men with higher levels to have dramatically higher rates of disease. That pattern is simply not observed.
Interestingly, low testosterone may actually suppress PSA production. This means:
Men with low testosterone may have lower PSA levels even when cancer is present.
Starting TRT can sometimes “unmask” previously silent disease—not because testosterone caused it, but because PSA production becomes more reflective of true prostate biology.
This reinforces why baseline testing and ongoing monitoring matter.
At Axios Health and Wellness, our approach is rooted in precision medicine and responsible hormone optimization. We prioritize:
Comprehensive baseline evaluation, including PSA testing and risk assessment.
Individualized treatment plans based on symptoms, labs, and health history.
Ongoing monitoring to ensure safety, effectiveness, and long-term health.
Shared decision-making so patients understand both benefits and risks.
We do not practice fear-based medicine—but we also do not ignore data. We follow the evidence.
The longstanding belief that testosterone inherently drives prostate cancer arose from early studies in men with advanced disease. Modern peer-reviewed research provides a more balanced understanding:
TRT does not appear to increase prostate cancer risk when appropriately prescribed.
PSA may rise modestly with treatment, but this alone does not indicate malignancy.
Aging remains the most significant risk factor for prostate cancer.
As science evolves, so should our conversations. Testosterone therapy is not about chasing supraphysiologic levels—it’s about restoring balance, improving quality of life, and doing so safely.
At Axios Health and Wellness, our mission is simple: deliver care that is informed, individualized, and grounded in modern medical evidence—not outdated dogma.
Charles Huggins & Clarence Hodges. Studies on prostatic cancer (1941).
Systematic reviews and meta-analyses examining testosterone therapy and prostate cancer incidence.
Studies evaluating PSA changes in older hypogonadal men treated with testosterone.
Contemporary reviews describing the androgen saturation model and prostate receptor biology.
